This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignees: Edigene Therapeutics (Beijing) Inc., Peking University. Active years: 2023.
Company Filing History:
1 out of 1 
1 out of 663 
Years Active: 2023
Title: Gangbin Tang: Pioneering Advances in RNA Editing
Introduction
Gangbin Tang, located in Beijing, China, is a notable inventor recognized for his contributions to the field of RNA editing. His innovation focuses on sophisticated methods and compositions that enhance the specificity and efficiency of RNA modification.
Latest Patents
Gangbin Tang holds a patent for "Methods and Compositions for Editing RNAs." This groundbreaking application outlines methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell. This facilitates the deamination of adenosine in a target RNA. The application further presents the deaminase-recruiting RNAs utilized in these RNA editing methods and related compositions.
Career Highlights
Throughout his career, Gangbin Tang has worked with esteemed institutions. He is associated with Edigene Therapeutics (Beijing) Inc. and Peking University. His roles in these organizations have equipped him with a robust foundation in biological research and innovation.
Collaborations
During his professional journey, Gangbin Tang has collaborated with several distinguished colleagues, including Pengfei Yuan and Yanxia Zhao, who have also contributed significantly to the realms of biotechnology and genetic research.
Conclusion
Gangbin Tang's work on RNA editing positions him at the forefront of genetic engineering and molecular biology, contributing valuable innovations to the scientific community. His patented methods not only represent a significant leap in RNA technology but also pave the way for future research and applications in various biomedical fields.